Nektar Therapeutics (NKTR) Capital Leases (2010 - 2017)

Nektar Therapeutics' Capital Leases history runs 8 years deep, the most recent figure standing at $3.0 million for Q3 2017.

• In Q3 2017, Capital Leases rose 39.99% year-over-year to $3.0 million; the TTM figure through Sep 2017 stood at $3.0 million (up 39.99% YoY), while the FY2016 annual figure was $2.2 million, up 107.18% from the prior year.
• Capital Leases was $3.0 million for Q3 2017 at Nektar Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $10.8 million in Q1 2013 to a low of $1.1 million in Q2 2017.
• Historically, Capital Leases has averaged $5.4 million across 5 years, with a median of $5.3 million in 2014.
• The sharpest annual moves came in 2016 and 2017: Capital Leases soared 107.18% in 2016, then plunged 80.14% in 2017.
• A 5-year view of Capital Leases shows it stood at $8.0 million in 2013, then tumbled by 48.58% to $4.1 million in 2014, then slumped by 74.08% to $1.1 million in 2015, then jumped by 107.18% to $2.2 million in 2016, then jumped by 34.95% to $3.0 million in 2017.
• The last three Capital Leases figures came in at $3.0 million (Q3 2017), $1.1 million (Q2 2017), and $1.6 million (Q1 2017), per Business Quant data.